Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed. Giving it after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying how well sunitinib works when given before and after
surgery in treating patients with stage IV kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania